Linezolid Fresenius Kabi

Linezolid, the active ingredient in Linezolid Fresenius Kabi, is an oxazolidinone presented as an intravenous solution for IV use. It is employed to treat serious bacterial infections caused by Gram‑positive organisms, including methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE), in adult patients requiring hospital care. The drug is indicated for infections of the skin, soft tissues, and the respiratory tract, and it is supplied in a sterile formulation suitable for infusion.

GNH USA supplies Linezolid Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is an oxazolidinone antibacterial indicated for several serious infections.

Complicated skin and soft tissue infections: provides bactericidal activity against resistant Gram‑positive pathogens, facilitating clinical cure. Methicillin‑resistant Staphylococcus aureus (MRSA) infections: eradicates MRSA strains in skin, lung and bloodstream infections. Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative therapy for infections where vancomycin is ineffective. Community‑acquired and hospital‑acquired pneumonia: treats pneumonia caused by susceptible organisms, improving respiratory function.

Linezolid may be associated with a range of adverse reactions, which are categorised by frequency and clinical severity.

Common Side Effects: - Nausea: mild to moderate stomach upset reported in many patients. - Diarrhea: loose stools occurring during therapy. - Headache: transient cranial discomfort. - Metallic taste: altered taste perception during infusion.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count that may lead to bleeding. - Peripheral neuropathy: nerve damage causing tingling or numbness, potentially irreversible. - Serotonin syndrome: risk when combined with serotonergic agents, presenting with agitation, hyperthermia, and autonomic instability.

When using Linezolid, clinicians should consider several safety measures. - Renal impairment: adjust therapy and monitor renal function in patients with reduced clearance. - Hepatic dysfunction: use cautiously and assess liver enzymes regularly. - Hematologic monitoring: perform complete blood counts weekly to detect anemia or thrombocytopenia. - Concomitant serotonergic drugs: avoid co‑administration due to risk of serotonin syndrome. - Store at ambient temperature: keep vials below 25 °C, protect from moisture and light, and retain in original packaging.

Linezolid can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: may precipitate serotonin syndrome; avoid concurrent use. - Monoamine oxidase inhibitors (MAOIs): increase risk of severe serotonin toxicity; co‑administration is contraindicated.

Moderate Interactions (Monitor Closely): - Rifampicin: induces hepatic enzymes and can reduce linezolid plasma concentrations; monitor efficacy. - Warfarin: may enhance anticoagulant effect; check INR more frequently. - Ethanol: linezolid is a reversible MAO inhibitor; caution with alcohol to prevent hypertensive reactions.